Science Links Japan | Dose-response of a Jelly Preparation of Calcium Polystyrene Sulfonate in Patients with Hyperkalemia (2nd report)-Changes in the Serum Potassium Level with or without RAS Inhibitor-

Dose-response of a Jelly Preparation of Calcium Polystyrene Sulfonate in Patients with Hyperkalemia (2nd report)-Changes in the Serum Potassium Level with or without RAS Inhibitor-

Accession number;06A0891771

Title;Dose-response of a Jelly Preparation of Calcium Polystyrene Sulfonate in Patients with Hyperkalemia (2nd report)-Changes in the Serum Potassium Level with or without RAS Inhibitor-

Author; TSUGE TOSHINAO (Juntendo Univ., JPN) NAKATA JUN'ICHIRO (Juntendo Univ., JPN) KOBAYASHI NORIYOSHI (Juntendo Univ., JPN) SUZUKI YUSUKE (Juntendo Univ., JPN) HAMADA CHIEKO (Juntendo Univ., JPN) HORIKOSHI SATOSHI (Juntendo Univ., JPN) TOMINO YASUHIKO (Juntendo Univ., JPN) WAKABAYASHI MICHIRO (Juntendo Univ., JPN) SATAKE KENJI (Juntendo Univ., JPN) SETO TAKUYA (Juntendo Univ., JPN) SHO ICHIYU (Shinjukugyoenshounaikakurinikku)

Journal Title;Ther Res

Journal Code:Y0681A

ISSN:0289-8020

VOL.27;NO.10;PAGE.2017-2026(2006)

Figure&Table&Reference;FIG.9, TBL.1, REF.20

Pub. Country;Japan

Language;Japanese

Abstract;Objectives: In this study, dose-response of the serum potassium lowering effect of a calcium polystyrene sulfonate (PS) preparation was investigated. Changes in the serum potassium level were also examined with or without a RAS inhibitor, which is said to increase the serum potassium level. Subjects and methods: Twenty-three patients diagnosed with hyperkalemia associated with chronic renal failure in conservative period were enrolled in this study. The study drug, PS-Ca jelly preparation (ARGAMATE Jelly), was started at a daily dose of one preparation (5 grams as PS-Ca), and the dose was increased by one preparation every month to finally reach three preparations a day. Blood samples were collected once a month and serum levels of creatinine and electrolytes were measured. Results: PS-Ca jelly decreased serum potassium levels in a dose-dependent manner. Decreases were 0.67mEq/L at 5 grams of PS-Ca/day, 1.06mEq/L at 10 grams/day, and 1.33mEq/L at 15 grams/day. Irrespective of the use of the RAS inhibitor, serum potassium levels were decreased significantly in a dose-dependentmanner. Further, little change in serum creatinine levels occurred in subjects in which the RAS inhibitor was used, although in subjects in which the RAS inhibitor was not used, serum creatinine level tended to gradually increase. Conclusion: Serum potassium levels were reduced in a dose-dependent manner by administration of 5 to 15 grams/day of PS-Ca, and it appeared that together with control of serum potassium levels, renal function should be maintained by continuous administration of RAS inhibitor. (author abst.)

Related Articles;